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OS (HR 2.820, P = 0.007), i.e., patients with high CTLA-
4+ lymphocyte density and CTLA-4low tumor cells had 
the best prognoses. These results indicated that CTLA-4 
expression in lymphocytes was associated with better prog-
nosis, but that in tumor cells was associated with worse 
prognosis. Patients’ CTLA-4 profiles might thus be used to 
predict the benefits and toxicity of CTLA-4 blockade.
Keywords Breast cancer · Disease-free survival · Overall 
survival · Cytotoxic T lymphocyte antigen 4 · CTLA-4
Abbreviations
ADCC  Antibody-dependent cell-mediated 
cytotoxicity
cSMAC  Central supramolecular activation cluster
CTLA-4  Cytotoxic T lymphocyte antigen 4
DFS  Disease-free survival
ER  Estrogen receptor
FCEP  Favorable CTLA-4 expression profile
HER2  Human epidermal growth factor receptor-2
OS  Overall survival
PBMC  Peripheral blood mononuclear cell
PR  Progesterone receptor
ROC analysis  Receiver-operating characteristic analysis
SBR grade  Scarff-Bloom-Richardson grade
Tregs  Regulatory T cells
Introduction
Tumor-derived immune dysregulation is a key feature 
of breast cancer. The immunosuppressive microenviron-
ment derived from breast cancer cells consists of cytokines 
and immune checkpoint molecules that can block anti-
tumor immunity [1–3]. One of these immune checkpoint 
Abstract To examine the relationship between cytotoxic 
T lymphocyte antigen 4 (CTLA-4) expression and breast 
cancer prognosis, CTLA-4 expression was immunohisto-
chemically detected in paraffin-embedded specimens of 
primary tumors from 130 patients with breast cancer who 
had a mean follow-up period of 112 months. CTLA-4 
expressed in cytoplasm of breast cancer cells and in cyto-
plasm and cell membranes of interstitial lymphocytes. 
Univariate analysis (log-rank) associated higher density 
of interstitial CTLA-4+ lymphocytes with longer DFS and 
OS, but higher tumor CTLA-4 expression with shorter OS. 
After controlling for age, clinical stage, Scarff-Bloom-
Richardson grade, tumor thrombus, ER, PR, HER2 and 
Ki-67, multivariate analysis (Cox) showed that density of 
interstitial CTLA-4+ lymphocytes independently predicted 
longer DFS (HR 0.315, P = 0.002) and OS (HR 0.313, 
P = 0.005), whereas tumor CTLA-4 expression indepen-
dently predicted shorter DFS (HR 2.176, P = 0.029) and 
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molecules is cytotoxic T lymphocyte antigen 4 (CTLA-
4, CD152). CTLA-4 is a CD28 homologue and shares 
two ligands—B7-1 (CD80) and B7-2 (CD86)—with 
CD28. CTLA-4 has much stronger binding affinity for 
the two ligands than CD28 [4]. CTLA-4 has three differ-
ent isoforms: the full-length isoform with an extracellular 
ligand-binding domain and an intracellular signal-trans-
ducing domain; the soluble isoform that consists only of 
the extracellular domain; and the third isoform (which has 
only been identified in mice), which lacks the extracellular 
domain [5].
CTLA-4 is normally expressed at low levels on the sur-
face of naive effector T cells and regulatory T cells (Tregs). 
After stimulation of a naive T cell through the T-cell recep-
tor, CD8+ T cells and CD4+ T cells, including Tregs, up-
regulate membrane CTLA-4 and secrete soluble CTLA-4 
[6–8]. As negative feedback to maintain immune self-tol-
erance and homeostasis, different CTLA-4 isoforms reduce 
T-cell activation through either intrinsic or extrinsic regula-
tion of T-cell activity. When CD28 binds B7 receptors on 
antigen-presenting cells and mediates activating signals 
in T cells, the full-length form of CTLA-4 binds B7 and 
initiates inhibitory signals via its intracellular signal-trans-
ducing domain, including cell-cycle arrest and decreased 
cytokine production. Upon T-cell activation, intracellular 
calcium levels are elevated, and secretary granules contain-
ing presynthesized soluble CTLA-4 are translocated to the 
central supramolecular activation cluster (cSMAC) within 
the immunological synapse to release the soluble CTLA-4. 
Soluble CTLA-4 interacts with B7, which excludes CD28 
from the cSMAC [9]. Ex vivo experiments showed solu-
ble CTLA-4 to inhibit human T-cell responses to antigen; 
blocking soluble CTLA-4 significantly enhanced anti-
gen-driven PBMC (peripheral Blood Mononuclear cell) 
responses [8].
Previous studies implicated CTLA-4 in immune dys-
regulation of breast cancer and found CTLA-4 to be highly 
expressed in breast tumor cells [10, 11]. Plasma soluble 
CTLA-4 and CTLA-4 expression in peripheral mononu-
clear cells of breast cancer patients were higher than in 
normal controls [10, 12, 13]. Nonetheless, the relationship 




This retrospective study included 130 patients who underwent 
breast cancer surgery between January 2000 and Decem-
ber 2002 at the People’s Liberation Army General Hospital, 
Beijing, China. The study was approved by the Institutional 
Review Board of the People’s Liberation Army General Hos-
pital. Informed consents were obtained from all the patients. 
Inclusion criteria include: (1) pathologically confirmed breast 
cancer, (2) availability of paraffin-embedded specimens of 
the primary tumor and (3) relatively complete follow-up data. 
Of 175 consecutive patients who underwent radical mastec-
tomies, we excluded 32 patients whose primary tumor speci-
mens were unavailable and 13 whose follow-up data were 
unavailable. Finally, 130 patients were included.
Immunohistochemistry
Serial paraffin-embedded sections (3 μm thick) from the 
130 patients were de-waxed with xylene and subsequently 
hydrated with an ethanol gradient. The tissue sections 
were subjected to high-pressure Tris–EDTA buffer (pH 
9.0) for antigen retrieval and then immersed in 3 % H2O2 
for 10 min to eliminate endogenous peroxidase activity. A 
working solution of normal goat serum was added to the 
tissue sections and incubated at 37 °C in a humidified box 
for 10 min to block nonspecific antigens. Sections were 
then incubated overnight at 4 °C with rabbit antihuman 
CTLA-4 IgG (1:100 dilution, bs-1179R, Beijing Biosyn-
thesis Biotechnology Co., Ltd, China) and then at 37 °C for 
30 min with a secondary antibody against rabbit and mouse 
immunoglobulins (ready-to-use, EnVision K500711, Dako, 
Denmark). Afterward, sections were stained with DAB for 
1 min, and nuclei were counterstained with hematoxylin. 
Slides were dehydrated in an ethanol gradient, mounted 
with neutral gum and stored for later observation. Sections 
of human tonsil specimens with confirmed high expression 
of the target molecules served as positive control. Sections 
incubated with the primary antibody diluent with no anti-
body were used as negative control 1; sections incubated 
with primary antibody (1:100 dilution, bs-1179R, Beijing 
Biosynthesis Biotechnology) premixed with CTLA-4 pep-
tide (bs-1179P, Beijing Biosynthesis Biotechnology) were 
used as negative control 2 (Supplementary Figure 1).
Imaging and data analysis
IHC slides were evaluated by two independent patholo-
gists who were unaware of patients’ clinical and prognostic 
information. Two variables—density of interstitial CTLA-
4+ lymphocytes and tumor CTLA-4+ expression—were 
evaluated as follows: interstitial CTLA-4+ cells in intersti-
tial areas adjacent to tumor nests were counted in 15 high-
power fields adjacent to tumor nests (400×) that were ran-
domly selected from the entire film under a Leica DM2000 
microscope. Interstitial CTLA-4+ cells per high-power field 
were counted; density of interstitial CTLA-4+ lymphocytes 
(average number of CTLA-4+ cells per mm2) was calcu-
lated by dividing positive cells by the area of high-power 
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fields (0.31 mm2). CTLA-4 expression in tumor cell cyto-
plasm was semiquantitatively scored based on staining 
intensity [14] (none: 0; weak: 1; moderate: 2; and strong: 3; 
examples in Supplementary Figure 2). Percentages of stain-
ing intensities in tumor cell cytoplasm were sequentially 
calculated as A, B, and C %. Tumor CTLA-4 expression 
(CTLA-4 intensity in tumor cell cytoplasm) was deter-
mined as (1 × A % + 2 × B % + 3 × C %).
Statistical analysis
Statistical analyses were performed using the SPSS 13.0 
statistical software package. Correlations between continu-
ous variables were assessed using the Spearman rank-sum 
test. Correlations between categorical variables and clin-
icopathological parameters were evaluated by employing 
Mann–Whitney U test or Kruskal–Wallis test. Nonpara-
metric receiver-operating characteristic (ROC) analysis was 
used to determine optimal cutoff values of variables for 
overall survival (OS). Patients were divided into high- and 
low-expression groups in terms of optimal cutoff values of 
tumor CTLA-4 expression (CTLA-4high and CTLA-4low) 
or density of interstitial CTLA-4+ lymphocytes (densityhigh 
and densitylow). These groups were subjected to univariate 
and multivariate survival analyses. For survival analysis, the 
Kaplan–Meier method was used. For univariate analysis of 
significance, the log-rank test or Cox analysis was used. The 
Cox proportional hazards model was used for multivariate 
analysis. P < 0.05 was considered as statistically significant.
With the actual OS as the gold standard, sensitivity and 
specificity for factors to predict survivals were determined 
by crosstabs. Predictive effects were determined by levels 
of sensitivity, specificity, Youden index and accuracy.
Patient characteristics
Clinicopathological data of enrolled subjects were summarized 
in Table 1. No patient received surgical castration, neo-adjuvant 
Table 1  Clinicopathological features of the 130 patients with breast 
cancer
Clinicopathological parameter N (%)
Age (years)
 ≤48 66 (50.8)
 >48 64 (49.2)
Menstrual status
 Premenopausal 82 (63.1)
 Postmenopausal 48 (36.9)
Pathological type
 Invasive ductal carcinoma 120 (92.3)
 Invasive lobular carcinoma 2 (1.5)
 Medullary carcinoma 3 (2.3)
 Mucinous carcinoma 2 (1.5)
 Invasive eczematous carcinoma of nippla 2 (1.5)




 T1 47 (36.2)
 T2 70 (53.8)
 T3 11 (8.5)
 T4 2 (1.5)
Lymph node metastasis
 N0 63 (48.5)
 N1 39 (30.0)
 N2 13 (10.0)
 N3 15 (11.5)
Clinical stage
 I 31 (23.8)
 IIA 42 (32.3)
 IIB 24 (18.5)
 IIIA 16 (12.3)
 IIIB 2 (1.5)
 IIIC 15 (11.5)
SBR grading
 I 17 (13.1)
 II 89 (68.5)
 III 24 (18.5)
Thrombosis
 Positive 30 (23.1)
 Negative 100 (76.9)
ER
 Positive 84 (64.6)
 Negative 46 (35.4)
PR
 Positive 74 (56.9)
 Negative 56 (43.1)
HER-2
 Positive 27 (20.8)
 Negative 103 (79.2)
Table 1  continued
Clinicopathological parameter N (%)
Adjuvant chemotherapy
 Yes 104 (80.0)
 No 26 (20.0)
Adjuvant radiotherapy
 Yes 80 (61.5)
 No 50 (38.5)
Adjuvant endocrine therapy
 Yes 71 (54.6)
 No 59 (45.4)
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chemotherapy or targeted therapy. Median follow-up was 
112 months (range 7.7–138.6 months). Of 33 patients who suf-
fered local recurrence or metastasis, 29 patients died. Disease-
free survival (DFS) and OS rates were 74.6 and 77.7 %, respec-
tively. Median DFS and OS were not obtained.
CTLA‑4 expression in breast cancer
CTLA-4 was expressed in cytoplasm and cell membrane 
of interstitial lymphocytes (Fig. 1a); CTLA-4+ discrete 
cytoplasmic dots were found in cytoplasm of tumor cells 
(Fig. 1b). The optimal OS cutoff value for tumor CTLA-4 
expression was 1.525 (sensitivity: 51.7 %; specificity: 
67.3 %; area under curve [AUC]: 0.537; SE = 0.069) and 
for density of interstitial CTLA-4+ lymphocytes was 33.44/
mm2 (sensitivity: 63.4 %; specificity: 69 %; AUC: 0.695; 
SE = 0.058) (ROC curves see Supplementary Figure 3).
Prognostic factors for DFS and OS in breast cancer
Univariate analysis revealed that clinical outcome was sig-
nificantly associated with established prognostic factors: 
age, clinical stage, Scarff-Bloom-Richardson (SBR) grade, 
tumor thrombus, estrogen receptor(ER) and progesterone 
receptor (PR) status, human epidermal growth factor recep-
tor-2(HER2) expression and Ki67, but no significant asso-
ciation was found between clinical outcome and adjuvant 
chemotherapy (Supplementary Table 1).
CTLA‑4 expression and its correlation 
with clinicopathological features
No correlation between CTLA-4 expression in tumor 
cells and interstitial lymphocytes was found. Density of 
interstitial CTLA-4+ lymphocytes was not correlated 
with age, menopausal status, clinical stage, SBR grade, 
tumor thrombus, ER, PR, HER2 or Ki67. Tumor CTLA-4 
expression was not correlated with age, clinical stage, SBR 
grade, tumor thrombus, ER, PR, HER2 and Ki67. Tumor 
CTLA-4high expression was related to post-menstrual status 
(Mann–Whitney U, P = 0.008).
Correlation between CTLA‑4 expression and DFS or 
OS
Univariate analysis (log-rank) showed that lymphocyte den-
sityhigh status was associated with longer DFS (P = 0.002) 
and OS (P = 0.004), but CTLA-4high tumors with shorter 
OS (P = 0.041) (Table 2). Multivariate analysis found that 
(after controlling for age, clinical stage, SBR grade, tumor 
thrombus, ER, PR, HER2 and Ki-67) CTLA-4+ lympho-
cyte densityhigh was an independent predictor of longer 
DFS (HR 0.315, 95 % CL 0.150–0.658, P = 0.002) and 
OS (HR 0.313, 95 % CL 0.139–0.703, P = 0.005), whereas 
tumor CTLA-4high was an independent predictor of shorter 
DFS (HR 2.176, 95 % CL 1.084–4.437, P = 0.029) and 
OS (HR 2.820, 95 % CL 1.337–5.950, P = 0.007). Clini-
cal stage and HER-2 were also independent predictors of 
shorter DFS and OS.
Survival by CTLA‑4 expression in tumor cells 
and density of primary tumor CTLA‑4+ interstitial 
lymphocytes
Patients were divided into four subgroups according to 
profiles of CTLA-4 expression in tumor cells and density 
of CTLA-4+ interstitial lymphocytes: Group 1 (densityhigh 
CTLA-4+ lymphocytes, CTLA-4low tumor cells), Group 
Fig. 1  Expression profiles of CTLA-4 in breast cancer. CTLA-4 was expressed in cytoplasm and cell membrane of interstitial lymphocytes (a); 
CTLA-4+ cytoplasmic dots were found in cytoplasm of tumor cells (b)
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2 (densityhigh CTLA-4+ lymphocytes, CTLA-4high tumor 
cells), Group 3 (densitylow CTLA-4+ lymphocytes, CTLA-
4low tumor cells) and Group 4 (densitylow CTLA-4+ lym-
phocytes, CTLA-4high tumor cells). Univariate analysis 
(log-rank) showed that DFS and OS were longer in Group 
1 than in Group 2 (DFS: P = 0.006; OS: P = 0.008), Group 
3 (DFS: P < 0.001; OS: P = 0.002) and Group 4 (P < 0.001 
for both DFS and OS). Groups 2, 3 and 4 did not signifi-
cantly differ in DFS or OS (P > 0.05) (Table 3).
These results revealed that densityhigh interstitial CTLA-
4+ lymphocytes to be a better prognosis factor only when 
tumor CTLA-4 expression was low (Group 1 vs. Group 
3), whereas CTLA-4high tumor cells were associated with 
worse prognosis only when density of interstitial CTLA-4+ 
lymphocytes was high (Group 1 vs. Group 2).
Correlation between favorable CTLA‑4 expression 
profile and prognosis
Based on the aforementioned analysis, we renamed 
Group 1 as the “favorable CTLA-4 expression profile” 
(FCEP) Group, and patients in Groups 2, 3 and 4 collec-
tively as the “Other Patients” Group. The HER-2+ rate 
was significantly lower in the FCEP Group than in Other 
Table 2  Univariate log-rank analysis of relationships between CTLA-4 expression and DFS, OS
Parameter Basis for grouping Number DFS OS
Recurrences Mean DFS (month) P value Deaths Mean OS (month) P value
Density of interstitial CTLA- 
4+ lymphocytes
≤33.44/mm2 57 22 103.383 0.002 20 108.629 0.004
>33.44/mm2 73 11 124.899 9 127.829
Tumor CTLA-4 expression ≤1.525 82 17 126.029 0.088 14 124.771 0.041
>1.525 48 16 103.607 15 110.287
Table 3  DFS and OS of groups divided by CTLA-4 expression profiles
Groups Tumor CTLA-4 expression Density of interstitial 
CTLA-4+ lymphocytes
Number Recurrences Mean DFS (month) Deaths Mean OS (month)
Group 1 ≤1.525 >33.44/mm2 45 3 133.332 2 134.782
Group 2 >1.525 >33.44/mm2 28 8 107.649 7 114.033
Group 3 ≤1.525 ≤33.44/mm2 37 14 105.984 12 112.736
Group 4 >1.525 ≤33.44/mm2 20 8 92.265 8 101.322
Fig. 2  Kaplan–Meier survival curves on the correlation between 
favorable CTLA-4 expression profile and prognosis. Patients with 
high density CTLA-4+ interstitial lymphocytes (>33.44/mm2) and 
low CTLA-4 expression intensity in tumor cells (≤1.525) were char-
acterized as the favorable CTLA-4 expression profile (FCEP) Group; 
the other patients were the Other Patients Group. Univariate analysis 
(log-rank) indicated that, the patients in FCEP group had longer DFS 
(a) and OS (b) than those of the Other Patients Group
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Patients Group (12.50 vs. 34.92 %, P = 0.048, Pear-
son Chi-square test). But the two groups did not signifi-
cantly differ in other clinical features. Univariate analy-
sis (log-rank) showed the DFS of FCEP Group (N = 43, 
events = 3, mean DFS = 133.332 months) was longer than 
DFS of Other Patients Group(N = 85, events = 30, mean 
DFS = 108.384 months; P < 0.001), and OS of FCEP 
Group (N = 43, events = 2, mean OS = 134.782 months) 
was longer than OS of Other Patients Group(N = 85, 
events = 27, mean OS = 111.471 months; P = 0.001) 
(Fig. 2). Multivariate analysis showed that (after control-
ling for age, clinical stage, SBR grade, tumor thrombus, 
ER, PR, HER2 and Ki-67) FCEP status independently 
predicted longer DFS (HR 0.148, 95 % CL 0.045–0.489, 
P = 0.002) and OS (HR 0.116, 95 % CL 0.027–0.495, 
P = 0.004). Clinical stage, SBR grade and HER-2 were 
also independent predictors of DFS and OS.
As a predictor of good prognosis (survivals), the FCEP 
Group (densityhigh CTLA-4+ lymphocytes, CTLA-4low 
tumor cells) was 42.6 % sensitive, 95.6 % specific and 
53.85 % accurate, and its Youden index was 38.2 %.
Discussion
Elevated soluble CTLA‑4 in tumor microenvironment 
associated with poor prognosis
The current study showed that CTLA-4 was expressed by 
tumor cells. CTLA-4+ dots in tumor cell cytoplasm looked 
like transport vesicles. Breast cancer cells reportedly also 
expressed CTLA-4, which was principally found in cyto-
plasm of cancer cells [10, 11]. Humans apparently pro-
duce both a full-length CTLA-4 isoform, found on cell 
membranes, and a soluble isoform of CTLA-4 (soluble 
CTLA-4) that only contains the extracellular domain [5]. 
An RT-PCR study of four breast cancer cell lines showed 
extracellular transcripts of CTLA-4 to be present in all four 
cell lines, but not the full-length form of CTLA-4 [11]. We 
therefore postulated that the CTLA-4+ dots in cytoplasm 
of breast cancer cells in the current study contained solu-
ble CTLA-4, apparently synthesized by tumor cells and 
transported into the tumor microenvironment by transport 
vesicles.
Soluble CTLA-4 reportedly inhibits T-cell immunity, 
and CTLA-4 blockade could reverse this process [5, 8, 15]. 
One animal experiment suggested that soluble CTLA-4 
plays a major role in immunosuppression, because selec-
tively blocking soluble CTLA-4 alone by a specific anti-
body without blocking the full-length CTLA-4 isoform had 
an inhibitory effect on melanoma metastasis in vivo, simi-
lar to that attained by blocking both soluble and full-length 
isoforms of CTLA-4 [8]. Thus, CTLA-4high expression in 
breast cancer cells might indicate an immunosuppressive 
tumor microenvironment, which could explain the associa-
tion between higher CTLA-4 expression in breast cancer 
cells and poor prognosis, as demonstrated by this study.
Moreover, use of ipilimumab (CTLA-4 antibody) 
depleted CTLA-4+ melanoma cell lines through antibody-
dependent cell-mediated cytotoxicity (ADCC), in vitro and 
in a mouse model [16], which implies that CTLA-4 block-
ade could both reverse immunosuppression in tumor micro-
environment and destroy CTLA-4+ tumor cells directly 
through ADCC.
Association between high density of CTLA‑4+ 
lymphocytes and good prognosis
CTLA-4 expression is low on the surfaces of naive T cells 
and is up-regulated after T-cell activation to maintain 
immune self-tolerance and homeostasis [5, 8]. We therefore 
inferred that high density of CTLA-4+ lymphocytes indi-
cates relatively strong immune function in the tumor micro-
environment; in the present study, patients with densityhigh 
interstitial CTLA-4+ lymphocytes in their tumors under-
standably had better prognosis.
Anti-CTLA-4 blockade also depleted intratumoral 
CTLA-4+ Treg cells by macrophages via ADCC in recent 
reports [17–19], which implies that CTLA-4 blockade can 
activate anti-tumor immunity in the presence of enough 
tumor-infiltrating lymphocytes (TILs).
Prognostic value of interstitial CTLA‑4+ lymphocytes 
density was affected by tumor CTLA‑4 expression
Although this study failed to associate tumor CTLA-4 
expression with density of interstitial CTLA-4+ lympho-
cytes, the prognostic value of interstitial CTLA-4+ lympho-
cytes density was affected by CTLA-4 expression in tumor 
cells. Densityhigh patients had a survival advantage only if 
tumor CTLA-4 expression was low. Based on the afore-
mentioned analysis, we believed that CTLA-4high tumor 
cells indicated high levels of soluble CTLA-4 in tumor 
microenvironment, which suppressed the function of lym-
phocytes that were activated when infiltrating tumors.
For patients of Group 2 (CTLA-4high tumor cells, den-
sityhigh CTLA-4+ lymphocytes), high levels of soluble 
CTLA-4 in the tumor microenvironment would suppress 
TIL anti-tumor immunity to no stronger than that of the 
densitylow groups, which would lead to poor prognosis. As 
Group 1/FCEP Group had the most favorable immunologi-
cal status (CTLA-4low tumor cells, densityhigh CTLA-4+ 
lymphocytes, indicative of active immune reaction), their 
superior prognosis among all patients made sense.
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Implication of CTLA‑4 expression profile 
for individualized immunotherapy
As a negative regulator of T-cell immunity, CTLA-4 is an 
attractive target for cancer immunotherapy. Altering the 
balance between CD28/B7 positive and CTLA-4/B7 nega-
tive regulatory signals may enhance anti-tumor immune 
response. However, remaining questions include (a) how 
far this balance can be shifted to be effective while avoid-
ing serious immunity-related adverse reactions and (b) how 
to monitor such a change in immune balance. In clinical 
trial, although only a subset of melanoma patients treated 
with anti-CTLA-4 antibody derived benefits, immunity-
related adverse events of different severities occurred in 
approximately 64.2 % of melanoma patients treated with 
anti-CTLA-4 antibody, some of which were lethal [20, 21].
A clinical trial of CTLA-4 blockade treatment for breast 
cancer showed that peripheral blood immune status was 
improved after CTLA-4 blockade in most patients, but 
good peripheral blood immune responses did not invariably 
translate into lasting beneficial outcomes [22]. This phe-
nomenon suggests that the immunosuppressive state of the 
tumor microenvironment is more potent and complicated 
than that in peripheral blood and, therefore, much more dif-
ficult to be overcome. An effective cancer immunotherapy 
should be able to induce effective anti-tumor immunity 
and, at the same time, remove tumor-induced immunosup-
pression in its microenvironment.
In this study, breast cancer patients were divided into 
four groups by their CTLA-4 expression profiles in tumor 
cells and primary TILs. These profiles could facilitate tai-
loring immunotherapeutic strategies to patients’ different 
immunological features.
Group 2 patients(CTLA-4high tumor cells, densityhigh 
CTLA-4+ lymphocytes) might benefit most from CTLA-4 
blockade treatment, because a sufficient number of preex-
isting inactive T cells in tumor microenvironment could 
be re-activated after neutralizing soluble CTLA-4 with 
CTLA-4 antibodies; ADCC against CTLA-4+ tumor cells 
might also be induced by CTLA-4 antibodies. For Group 
4 patients (CTLA-4high tumor cells, densitylow CTLA-4+ 
lymphocytes), CTLA-4 blockade alone would not induce 
an effective anti-tumor immunity given the paucity of 
preexisting TILs; combination therapies aimed at elicit-
ing anti-tumor immunity are needed. CTLA-4 blockade 
might not benefit patients in Groups 1 and 3 (those with 
CTLA-4low tumor cells) because of the scant levels of solu-
ble CTLA-4 to neutralize. Moreover, given an adequate 
number of preexisting active T cells in the Group 1 tumor 
microenvironment, the balance between CD28/B7 posi-
tive and CTLA-4/B7 negative regulatory signals may be 
overthrown by CTLA-4 blockade, thus evoking excessive 
immune response and immunity-related toxicity.
Conclusion
We found CTLA-4 expression in primary breast cancer 
lesions to have potential prognostic value; higher CTLA-4 
expression in breast cancer cells was associated with worse 
prognosis, and higher density of interstitial CTLA-4+ lym-
phocytes with better prognosis. However, high CTLA-4+ 
lymphocyte density was significantly correlated with good 
prognosis only when tumor CTLA-4 expression was low. 
CTLA-4 expression varied greatly among breast cancer 
patients; we identified CTLA-4 expression profiles in terms 
of CTLA-4 expression in lymphocytes and tumor cells. We 
speculated that these immunological features might be asso-
ciated with clinical efficacy and adverse reactions to CTLA-4 
blockade treatment and should help to guide immunothera-
peutic strategies. Further studies of immunotherapies guided 
by individual variation in immune status are warranted.
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